Although COVID-19 remains the driving force, non-pandemic-related strategic deal making continues. Among the most impactful deals announced in December is the partnership among Renown Institute for … [Read more...]
DX Earnings Report
Q3 Creates the Perfect Storm of Sustained COVID-19 Tailwinds and Diminishing Headwinds
December 2, 2020
July through September 2020 was a remarkable quarter for most diagnostics firms. In fact, it was the closest thing to a perfect storm for earnings. Pandemic tailwinds drove massive revenues for firms … [Read more...]
Diagnostic Deals
Labs, Universities and Even Computer Companies Target Point-of-Care COVID-19 Test Development
April 1, 2020
The imperative to create and provide tests capable of detecting the SARS-CoV-2 virus that causes COVID-19 coronavirus continues to fuel strategic deal making. SARS-CoV-2 point-of-care tests was the … [Read more...]
DIAGNOSTIC DEALS
Diagnostic Deals: Urgent Need for Coronavirus Diagnostics Fuels Strategic Collaboration
March 1, 2020
Not surprisingly, teaming up for development and commercialization of coronavirus (COVID-19) detection and vaccination products was a major theme of strategic alliance making during the period. … [Read more...]
DIAGNOSTIC DEALS
Diagnostic Deals: Lab Corp & Quest to Continue Targeting Small and Independent Labs for Acquisition
January 31, 2020
PAMA price cuts were supposed to drive consolidation in the lab market. The expectation was that price pressures would make it impossible for smaller labs to remain independent, rendering them juicy … [Read more...]
DIAGNOSTIC DEALS
Diagnostic Deals: Illumina/PacBio Merger Derails & Qiagen Takes Itself Out of Play
December 31, 2019
As 2019 came to a close, the biggest story in DX deal making was the pair of anticipated M&A deals that suddenly seem unlikely to happen. As a result, two major genetic testing companies will … [Read more...]
DIAGNOSTIC DEALS
Diagnostic Deals: The Fate of Illumina-PacBio Merger Hangs in the Balance
November 30, 2019
Will they or won’t they? The suspense continues over whether Illumina’s proposed rescue of Pacific Biosciences will actually close. The $1.2 billion cash merger, which was originally expected to close … [Read more...]
DIAGNOSTIC DEALS
Diagnostic Deals: A roundup of the key mergers, acquisitions, alliances, licenses and other strategic transactions from the past month
October 31, 2019
Although briskness in alliances partially offset sluggishness in M&A, October was far less dynamic than September for strategic deal making within the diagnostics sector. Here’s an overview of the … [Read more...]
DIAGNOSTIC DEALS
Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month
September 30, 2019
After a brief summer lull, strategic deal making ramped up in September, especially in alliance making where volume nearly doubled last month’s levels. Here’s an overview of the long-term trends and … [Read more...]
DIAGNOSTIC DEALS
Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month
August 29, 2019
Big picture-wise, health care industry mergers and acquisitions during the second quarter were up 7.3% from the first quarter and topped 250 deals for the eighth quarter in a row, according to … [Read more...]
